Skip to content

Intco Medical Technology Stock

300677.SZSHZ

Intco Medical Technology Co., Ltd., HealthcareISIN CNE100003456

$7.23▼ $0.41 (−5.4%)Closing price of 20 Nov 2026

45Score 45 out of 100, Weak

Turn on early warning

Price and Trend

62 / 100

Price history

+24% in one year

The chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.

Long-term trend

Below the 200-day line: the price is 0.6% below it.

Trend change

Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.

Momentum

Normal: the price is neither overheated nor sold off (RSI 68).

Distance to the high

The price is 27% below its 52-week high. Largest decline in 9 years: 89% (January 2021 to February 2024).

Chart figures for advanced users
SMA 50$7.13
Average price of the last 50 trading days, shows the short-term trend.
SMA 200$7.27
Average price of the last 200 trading days, shows the long-term trend.
RSI (14)68
Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
MACDabove the signal line
Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
Support$5.61
The lowest closing price of the last twelve months.
Resistance$9.85
The highest closing price of the last twelve months.
Market cap
$5B
Div. yield
0.39%
12 months
108.9
earnings collapsed, on expected earnings 12.2
12.9
on earnings for the next twelve months ($0.59 per share)
Fair value
$8.00

Snapshot

Computed from the data by fixed rules, no AI

  • Intco Medical Technology Co., Ltd. belongs to the Medical (Instruments & Supplies) industry (China) and, with a market value of $4.73B, is number 23 of 46 companies in its industry on MEQIRI.
  • In fiscal 2025 it reported revenue of $1.49B (up 4.2% year on year) and earnings of $151.6M (down 31%).
  • For fiscal 2026, analysts expect on average revenue of $2.16B (up 45.2%) and adjusted earnings per share of $0.40 (up 1.5%).
Show more
  • MEQIRI Score 45 out of 100 (Weak): rank 419 of 686 in Healthcare, median 53.
  • The P/E is 103 because earnings over the last twelve months collapsed; on the expected earnings of the next twelve months it is 12.2 (Healthcare sector median 30.9). The P/E therefore does not count in the score.
  • Our model puts fair value at $8.00, with the price 5% below it.

In Plain Words

The numbers on this page in plain words, written by an AI

Strengths

  • Earnings Turn into CashFree cash flow above 500% of earnings over the last 12 months.Fundamentals 67
  • Consistently ProfitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 67

Weaknesses

  • DilutionShare count up 79% since 2020.Capital allocation 27
  • Earnings per Share FallingDown 33.6% a year since 2020.Growth 13
  • Revenue ShrinkingRevenue down 6.4% a year since 2020.Growth 13
45/ 100
MEQIRI Score
Weak

Its standout strength is momentum, while capital allocation and growth hold the score back.

Daily figure as of 20 Nov 2026

How the score is calculated

Score Overview

The fundamentals are in the middle range.

Profit consistency100% of years
Cash conversion (free cash flow to earnings, 12 months)above 500%
ROIC (12 months)5.3%
Positive free cash flow30% of years
How this category is measured

Score History

The full history of up to 20 years comes with MEQIRI Pro.

See plans

Crash Risk not measured

How Well MEQIRI Warns

For stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.

Valuation

Valuation Signal

Fairly valued
Price
$7.64
Fair value
$8.00
Gap to fair value
−5%

Closing price of 19 Nov 2026, used by the daily score.

In our model the price counts as cheap below $5.72 and expensive above $13.34 (uncertainty high, based on the price swings of the past year).

Calculated with a cost of equity of 7.9%. At 8.9% the fair value would be $6.63, at 6.9% it would be $9.98.

Valuation metrics

2.5
15
Fair value (model)
$8.00

From the cash-flow model alone; after a one-off collapse in earnings there is no industry value.

Calculate with your own assumptions

Company Performance

This shows several years of history with an automatic assessment.

Revenue

13 years

In the twelve months to 30 Sep 2026, revenue rose 33.2% on the twelve months before. Revenue has grown strongly since 2013, at around 25% per year.

Margins

13 years
  • Gross margin
  • Operating margin
  • Net margin

In fiscal 2025: gross 24%, operating 12%, net 10%. Last 12 months: net 2%.

Debt & balance sheet

latest quarter
0.95
4.3x
0.6
Cash & equivalents
$1.21B

Moderate debt, and interest is adequately covered.

Earnings

Next earnings
28 Apr 2027in 159 days
Last reported
28 Oct 2026EPS reported −$0.15

What Happened at Intco Medical Technology

The key events of the last six months from our own data. A click takes you to the matching card.

Sector Comparison

686 rated companies in Healthcare

Rank 419 of 686
419/ 686
This company
45
Sector median
53

Categories Against the Sector Median

ProfitabilityMedian of 686 companies32 (median 39)7 below the median
GrowthMedian of 686 companies13 (median 54)41 below the median
FundamentalsMedian of 686 companies67 (median 49)18 above the median
ValuationMedian of 470 companies with a value59 (median 58)1 above the median
StabilityMedian of 686 companies40 (median 68)28 below the median
Capital allocationMedian of 686 companies27 (median 41)14 below the median
Technical analysisMedian of 686 companies62 (median 61)1 above the median
MomentumMedian of 686 companies76 (median 64)12 above the median

The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.

Competitors in Medical (Instruments & Supplies)

The next larger and next smaller companies by market value

ETFs That Hold Intco Medical Technology

Held by 4 of the 100 largest US ETFs. Shown per index: the ETF with the largest weight.

ETFWeightCostFund size
Vanguard FTSE Emerging Markets ETFVWO0.00%0.06%$117.5B
Vanguard FTSE All-World ex-US ETFVEU0.00%0.04%$66.3B
Vanguard Total International Stock ETFVXUS0.00%0.05%$160.6B
Show 1 more

Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).

Data Status and Sources

Score
Daily value of 20 Nov 2026, recalculated nightly
Price
Closing price of 20 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Currency
Amounts in US dollars, converted at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.

Mandatory Disclosures for This Rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 1 May 2026)
  • Valuation signal Fairly valued since 20 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.